Payment overview · 2025
General Payments
$22.61
1 reported records · 1 companies
Healthcare provider profile · identity verified
Kent D. Carpenter, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · HUNTERSVILLE, NC · NPI 1871556092
Verified facts
What the public records show
CMS Open Payments records show Kent D. Carpenter, M.D. received $22.61 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $22.61 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $22.61 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $22.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 620 | 175 |
| Amlodipine Besylate | Amlodipine Besylate | 585 | 169 |
| Hydrochlorothiazide | Hydrochlorothiazide | 389 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 372 | 91 |
| Pravastatin Sodium | Pravastatin Sodium | 372 | 111 |
| Lisinopril | Lisinopril | 290 | 78 |
| Omeprazole | Omeprazole | 274 | 68 |
| Tamsulosin Hcl | Tamsulosin Hcl | 242 | 66 |
| Metoprolol Succinate | Metoprolol Succinate | 208 | 59 |
| Losartan Potassium | Losartan Potassium | 198 | 53 |
| Metformin Hcl Er | Metformin Hcl | 187 | 56 |
| Gabapentin | Gabapentin | 184 | 55 |
| Sertraline Hcl | Sertraline Hcl | 165 | 46 |
| Metformin Hcl | Metformin Hcl | 153 | 44 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 148 | 42 |
| Glimepiride | Glimepiride | 145 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 41 |
| Verapamil Er | Verapamil Hcl | 139 | 34 |
| Potassium Chloride | Potassium Chloride | 138 | 44 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 138 | 42 |
| Furosemide | Furosemide | 132 | 36 |
| Alprazolam | Alprazolam | 129 | 31 |
| Eliquis | Apixaban | 118 | 21 |
| Simvastatin | Simvastatin | 118 | 34 |
| Indapamide | Indapamide | 112 | 32 |
| Allopurinol | Allopurinol | 102 | 33 |
| Famotidine | Famotidine | 96 | 20 |
| Ramipril | Ramipril | 92 | 29 |
| Finasteride | Finasteride | 91 | 24 |
| Trazodone Hcl | Trazodone Hcl | 90 | 20 |
| Telmisartan | Telmisartan | 85 | 21 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 21 |
| Irbesartan | Irbesartan | 77 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 75 | 21 |
| Synthroid | Levothyroxine Sodium | 75 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 72 | 21 |
| Meloxicam | Meloxicam | 72 | 24 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 71 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 71 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 65 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 59 | 17 |
| Spironolactone | Spironolactone | 53 | 12 |
| Benztropine Mesylate | Benztropine Mesylate | 52 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 50 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 48 | 13 |
| Ezetimibe | Ezetimibe | 48 | 16 |
| Xarelto | Rivaroxaban | 46 | 13 |
| Enalapril Maleate | Enalapril Maleate | 45 | suppressed |
| Atenolol | Atenolol | 44 | 15 |
| Jardiance | Empagliflozin | 44 | 11 |
| Terazosin Hcl | Terazosin Hcl | 44 | 11 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 43 | 17 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 41 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 41 | suppressed |
| Pregabalin | Pregabalin | 40 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 39 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | 11 |
| Celecoxib | Celecoxib | 37 | 11 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 36 | suppressed |
| Klor-Con M20 | Potassium Chloride | 36 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 36 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 36 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 32 |
| Olanzapine | Olanzapine | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 33 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 33 | suppressed |
| Hydrocortisone | Hydrocortisone | 33 | 17 |
| Doxazosin Mesylate | Doxazosin Mesylate | 32 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 30 | suppressed |
| Lovastatin | Lovastatin | 30 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 30 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 30 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 29 | 14 |
| Prednisone | Prednisone | 29 | 19 |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 28 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 27 | 13 |
| Pioglitazone Hcl | Pioglitazone Hcl | 26 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 25 | suppressed |
| Carvedilol | Carvedilol | 24 | suppressed |
| Ketoconazole | Ketoconazole | 24 | 13 |
| Ozempic | Semaglutide | 24 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 23 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 23 | suppressed |
| Fenofibrate | Fenofibrate | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Lactulose | Lactulose | 22 | suppressed |
| Lorazepam | Lorazepam | 22 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 22 | 12 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Cephalexin | Cephalexin | 21 | 19 |
| Methimazole | Methimazole | 21 | suppressed |
| Risperidone | Risperidone | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 20 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 20 | suppressed |
| Mirtazapine | Mirtazapine | 20 | suppressed |
| Niacin Er | Niacin | 20 | suppressed |
| Temazepam | Temazepam | 20 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 20 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Diazepam | Diazepam | 17 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 13 |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Haloperidol | Haloperidol | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Carbamazepine | Carbamazepine | 15 | suppressed |
| Clonazepam | Clonazepam | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Memantine Hcl | Memantine Hcl | 14 | suppressed |
| Phenobarbital | Phenobarbital | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Dexamethasone | Dexamethasone | 13 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Levocarnitine | Levocarnitine | 13 | suppressed |
| Methocarbamol | Methocarbamol | 13 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 13 | suppressed |
| Phenytoin | Phenytoin | 13 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 13 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 13 | suppressed |
| Trihexyphenidyl Hcl | Trihexyphenidyl Hcl | 13 | suppressed |
| Verapamil Sr | Verapamil Hcl | 13 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 12 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 12 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 12 | suppressed |
| Dulera | Mometasone/Formoterol | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Thioridazine Hcl | Thioridazine Hcl | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Acarbose | Acarbose | 11 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 11 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 11 | suppressed |
| Metolazone | Metolazone | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Uloric | Febuxostat | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $22.61 · 1 records | Novo Nordisk Inc | Wegovy | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Novo Nordisk Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error